Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU EBITDA Margin

EBITDA as a percentage of revenue.

Caribou Biosciences, Inc.NASDAQ: CRBU

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -1019.4%

EBITDA Margin was -1019.4% in Q1 FY2026, up 630.6 pp from a year earlier. On a trailing-twelve-month basis it was -999.5%, up 475.3 pp year over year. Over 3 fiscal years it narrowed by 608.7 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -914.4% for the fiscal year ending Dec 2026, up from -1299.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-1019.4%-350.7 pp QoQ
Last fiscal yearDec 2025
-1299.7%+153.1 pp YoY
LTMMar 2026
-999.5%+475.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+630.6 pp-123.6 pp-754.2 pp
1 year+153.1 pp+385.2 pp+232.2 pp
3 years-608.7 pp-615.5 pp-6.8 pp
5 years+984.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1299.7%
Year-over-year change
+153.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CRBU compares with its peers on the latest reported figures

  • CRBU's LTM Mar 2026 EBITDA Margin of -999.5% is the 6th highest of the 9 companies compared; the peer median is -501.6%.
  • Its year-over-year change of +475.3 pp is the 3rd highest of 7, against a peer median of +72.6 pp.
  • Over three fiscal years its change of -608.7 pp compares with a peer median of +30.0 pp.
CRBU Competitors Peer median
EBITDA Margin for CRBU and competitors
Company Period LTM level YoY 3-year change
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-67.3% +67.9 pp+30.0 pp
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-161.1% +2125.8 pp+792.0 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-257.0% +77.3 pp+319.4 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-455.3% +1345.3 pp—
PYXSPyxis Oncology, Inc.LTM Mar 2026-547.9% ——
CRBUCaribou Biosciences, Inc.LTM Mar 2026-999.5% +475.3 pp-608.7 pp
IVAInventiva S.A.FY2025-2858.6% -1048.1 pp-2396.4 pp
HUMAHumacyte, Inc.LTM Mar 2026-3956.7% -3182.9 pp-1247.4 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-33540.9% ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
AARDAardvark Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding CRBU) -501.6%+72.6 pp+30.0 pp

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.